Emil D Kakkis Ultragenyx Pharmaceutical Inc. (RARE) insider trading activity

Emil D Kakkis is President & CEO of Ultragenyx Pharmaceutical Inc.. Currently has a direct ownership of 641,731 shares of RARE, which is worth approximately $25.1 Million. The most recent transaction as insider was on Mar 03, 2025, when has been sold 73,434 shares (Common Stock) at a price of $42.1 per share, resulting in proceeds of $3,091,571. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 642K

14.44% 3M change

14.44% 12M change

Total Value Held $25.1 Million

EMIL D KAKKIS Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 03 2025	SELL Open market or private sale	$3,091,571 $42.1 p/Share	73,434 Reduced 10.27%	641,731 Common Stock
Mar 01 2025	BUY Grant, award, or other acquisition	-	150,560 Added 17.39%	715,165 Common Stock
Mar 01 2024	SELL Payment of exercise price or tax liability	$935,118 $53.69 p/Share	17,417 Reduced 3.01%	560,781 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	41,560 Added 6.86%	563,913 Common Stock
Feb 07 2024	SELL Open market or private sale	$1,350,000 $45.0 p/Share	30,000 Reduced 5.27%	539,770 Common Stock
Dec 29 2023	SELL Open market or private sale	$1,436,100 $47.87 p/Share	30,000 Reduced 5.0%	569,770 Common Stock
Oct 19 2023	SELL Open market or private sale	$1,604,032 $33.52 p/Share	47,853 Reduced 7.39%	599,743 Common Stock
Oct 19 2023	BUY Exercise of conversion of derivative security	$328,271 $6.86 p/Share	47,853 Added 6.89%	647,029 Common Stock
Mar 01 2023	SELL Payment of exercise price or tax liability	$736,791 $45.65 p/Share	16,140 Reduced 2.62%	599,176 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	54,916 Added 8.19%	615,606 Common Stock
Dec 30 2022	SELL Open market or private sale	$892,351 $45.57 p/Share	19,582 Reduced 3.49%	541,108 Common Stock
Mar 01 2022	SELL Payment of exercise price or tax liability	$819,354 $67.37 p/Share	12,162 Reduced 2.05%	582,185 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	52,041 Added 7.58%	634,226 Common Stock
Oct 14 2021	SELL Payment of exercise price or tax liability	$69,093 $81.0 p/Share	853 Reduced 0.14%	594,347 Common Stock
May 06 2021	SELL Payment of exercise price or tax liability	$98,585 $115.71 p/Share	852 Reduced 0.14%	595,200 Common Stock
Mar 01 2021	SELL Payment of exercise price or tax liability	$2,328,245 $142.47 p/Share	16,342 Reduced 2.67%	596,052 Common Stock
Mar 01 2021	BUY Grant, award, or other acquisition	-	33,453 Added 5.18%	612,394 Common Stock
Oct 14 2020	SELL Payment of exercise price or tax liability	$78,972 $92.69 p/Share	852 Reduced 0.14%	610,189 Common Stock

EDK

Emil D Kakkis

President & CEO

Novato, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RARE shares.

Notify only if

Value

Insider Trading

Get notified when an Ultragenyx Pharmaceutical Inc. insider buys or sells RARE shares.

Notify only if

Operation

Value

Type

News

Receive news related to Ultragenyx Pharmaceutical Inc.

Track Activities on RARE

Account